Connect with us

Health

New pancreatic cancer treatment ‘wakes up’ immune cells, researchers say

Published

on

New pancreatic cancer treatment ‘wakes up’ immune cells, researchers say

NEWYou can now listen to Fox News articles!

Scientists have created a new antibody treatment that helps the immune system recognize and attack pancreatic cancer.

Pancreatic cancer cells use a sugary “disguise” to trick the immune system into ignoring them.

Most current cancer immunotherapies target proteins or genes, but this new therapy focuses on the sugars on the cell surface, blocking them so that immune cells can find and attack the cancer, according to researchers from Northwestern University in Chicago.

CANCER VACCINE SHOWS PROMISE IN PREVENTING RECURRENCE OF PANCREATIC, COLORECTAL TUMORS

Advertisement

“Pancreatic cancer is notoriously good at hiding from the immune system, but we were struck that a single sugar, called sialic acid, can so powerfully fool immune cells,” senior author Mohamed Abdel-Mohsen, associate professor of medicine in the division of infectious diseases at Northwestern University Feinberg School of Medicine, told Fox News Digital. 

“When tumors sugar-coat themselves with this molecule, it flips an immune ‘off switch’ on certain immune cells, essentially signaling, ‘I’m a normal, healthy cell; don’t attack.’”

Study authors Mohamed Abdel-Mohsen (top) and Pratima Saini (foreground) are pictured in Abdel-Mohsen’s lab. (Northwestern University)

In mice studies, the therapy was shown to be successful in blocking this sugar signal, “waking up” immune cells and slowing cancer’s growth.

In two mouse models, tumors treated with the antibody grew significantly slower than groups that did not receive the treatment, the study showed.

Advertisement

CANCER SURVIVAL APPEARS TO DOUBLE WITH COMMON VACCINE, RESEARCHERS SAY

These findings could pave the way toward testing in human groups, and could potentially be combined with chemotherapy and existing immunotherapies, according to the researchers.

The findings were published in the journal Cancer Research on Nov. 3.

Study senior author Mohamed Abdel-Mohsen is shown in his lab. “This is early-stage, preclinical research, not a treatment today, but it opens a new immune target in pancreatic cancer,” he said. (Northwestern University)

“This is early-stage, preclinical research, not a treatment today, but it opens a new immune target in pancreatic cancer,” said Abdel-Mohson.

Advertisement

Heloisa P. Soares, M.D., Ph.D., medical director of theranostics at Huntsman Cancer Institute and associate professor of internal medicine at the University of Utah, said this research is “encouraging” because it points to a new way of helping the immune system recognize and fight pancreatic cancer.

“Pancreatic cancer is notoriously good at hiding from the immune system.”

“It was surprising to learn that a protein usually responsible for helping cells stick together is also being used by pancreatic cancer as a hidden ‘do-not-attack’ signal,” Soares, who was not involved in the study, told Fox News Digital.

“The striking part was that when this signal was blocked, the immune cells woke back up and started attacking the tumor much more effectively — which suggests a promising new direction for treatment.”

CANCER TREATMENT COULD BE LESS EFFECTIVE IF PATIENTS CONSUME POPULAR SWEETENER

Advertisement

Pancreatic cancer is one of the most lethal forms of the disease. It’s usually detected at an advanced stage, leaving patients with limited treatment choices and a five-year survival rate of only about 13%, the researchers noted.

Unlike many other cancers, it often doesn’t respond to immunotherapy.

Pancreatic cancer is usually detected at an advanced stage, leaving patients with limited treatment choices and a five-year survival rate of only about 13%. (iStock)

“Pancreatic cancer is often diagnosed late, in part because it remains asymptomatic and is deep in the body,” Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital.

“It is also difficult to treat because it doesn’t have many good immune targets and doesn’t mutate that much.”

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The study did have some limitations, the researchers acknowledged — primarily that the tests have only been conducted on animals thus far and there is not yet any human data.

“Animal models cannot capture all the complexity of human pancreatic cancer,” the lead researcher noted. “Tumors also use multiple escape routes, so this strategy will likely be part of a combination approach.”

After human trials, the researchers estimate that it could take about five years before the therapy would be available to patients. (Northwestern University)

The long-term safety and dosing parameters of the therapy are also unknown.

Advertisement

“We need clinical trials to see how effective this is in humans and whether it has a role in cancer treatments for this difficult and deadly cancer — but it is quite promising,” Siegel added.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The research team is now working with clinicians at Northwestern’s Robert H. Lurie Comprehensive Cancer Center on next steps toward potential human studies, likely in combination with current chemotherapy and immunotherapies, according to Abdel-Mohsen.

“It’s a promising step forward, but not something that will change care overnight.”

“If future studies support it, this approach could be added to the toolbox against pancreatic cancer, likely alongside existing chemo-immunotherapy, not replacing what’s working today,” he told Fox News Digital.

Advertisement

After human trials, the researchers estimate that it could take about five years before the therapy would be available to patients.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Soares added, “It’s a promising step forward, but not something that will change care overnight. Continued funding and participation in clinical trials are essential to keep this progress moving.”

CLICK HERE FOR MORE HEALTH STORIES

The study was supported in part by the National Institutes of Health.

Advertisement

Health

GLP-1 Drugs Linked to Osteoporosis and Gout: Here’s How To Stay Safe

Published

on

GLP-1 Drugs Linked to Osteoporosis and Gout: Here’s How To Stay Safe


Advertisement




GLP-1 Drugs Linked To Increased Risk of Osteoporosis and Gout | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Ozempic-style drugs could slash complication risks after heart attacks, research suggests

Published

on

Ozempic-style drugs could slash complication risks after heart attacks, research suggests

NEWYou can now listen to Fox News articles!

A popular class of weight-loss drugs may prevent life-threatening cardiac complications by opening microscopic blood vessels that often remain blocked after a heart attack, according to a study published this week in Nature Communications.

The research, led by the University of Bristol and University College London, identified a biological brain-gut-heart signaling pathway. 

This discovery appears to explain how GLP-1 drugs — which mimic glucagon-like peptide-1, a hormone that helps regulate blood sugar and appetite — protect heart tissue from a condition known as “no-reflow.”

“In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” Dr. Svetlana Mastitskaya, the study’s lead author and a senior lecturer at Bristol Medical School, said in a press release.

Advertisement

“This results in a complication known as ‘no-reflow,’ where blood is unable to reach certain parts of the heart tissue.”

In nearly half of all heart attack patients, tiny capillaries (blood vessels) remain narrowed even after the main blocked artery is cleared. (iStock)

This lack of blood flow increases the risk of heart failure and death within a year. GLP-1 medications could prevent this, according to the researchers.

How it works

When the GLP-1 hormone is released in the gut or administered as a drug, it sends a signal to the brain, which then sends a signal to the heart that switches on special potassium channels in tiny cells called pericytes.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Advertisement

When these channels open, the pericytes relax, which allows the small blood vessels (capillaries) to widen and improve blood flow to the heart muscle, the researchers noted.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The new study used animal models and cellular imaging to track how GLP-1 interacts with heart tissue. When the researchers removed the potassium channels, the drugs no longer protected the heart — confirming they play a key role.

The findings suggest that existing GLP-1 medications, already used for type 2 diabetes and obesity, could be repurposed as emergency treatments. (iStock)

The findings suggest that existing GLP-1 medications, already used for type 2 diabetes and obesity, could be repurposed as emergency treatments during or immediately after a heart attack to reduce tissue damage.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

The researchers noted several limitations, including that the study relied on animal models.

Clinical trials are necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans.

While the study highlights the drug’s immediate benefits during a heart attack, it des not establish whether long-term use of these drugs provides a pre-existing level of protection. (iStock)

Additionally, while the study highlights the drug’s immediate benefits during a heart attack, it does not establish whether long-term use of the medication provides a pre-existing level of protection.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The research was primarily funded by the British Heart Foundation.

Related Article

Eating oatmeal for two days has unexpected impact on heart health, study suggests
Advertisement
Continue Reading

Health

Do collagen supplements really improve skin? Major review reveals the truth

Published

on

Do collagen supplements really improve skin? Major review reveals the truth

NEWYou can now listen to Fox News articles!

Collagen supplements have exploded in popularity, touted as everything from an anti-aging miracle to a muscle recovery booster.

But a sweeping new review conducted by U.K. researchers suggests that while collagen may help improve skin elasticity and ease arthritis pain, it does little for athletic performance or wrinkle reduction.

Researchers from Anglia Ruskin University analyzed 16 systematic reviews and 113 randomized controlled trials involving nearly 8,000 participants worldwide, which they say is the most extensive evaluation of collagen’s health effects to date. 

The review found consistent evidence that collagen supplementation improves skin elasticity and hydration over time and provides significant relief from osteoarthritis-related joint pain and stiffness, according to findings published in Aesthetic Surgery Journal Open Forum. 

Advertisement

A large U.K. review found that collagen supplements may improve skin elasticity and hydration over time. (iStock)

The researchers, however, did not find meaningful improvements in post-exercise muscle recovery, soreness or tendon mechanical properties (strength, springiness and stretch resistance).

“Collagen is not a cure-all, but it does have credible benefits when used consistently over time, particularly for skin and osteoarthritis,” co-author Lee Smith, professor of public health at Anglia Ruskin University, said in a statement.

EXPERIMENTAL SERUM SHOWS PROMISE IN REVERSING BALDNESS WITHIN 20 DAYS

“Our findings show clear benefits in key areas of healthy aging, while also dispelling some of the myths surrounding its use,” Smith added.

Advertisement

Collagen, the most abundant protein in the body, supports skin, bones, tendons, cartilage and connective tissue, according to experts. Natural collagen production begins to drop in early adulthood and declines more sharply with age.

The study found that collagen supplements may help reduce joint pain and stiffness in people with osteoarthritis. (iStock)

The review found that long-term collagen supplementation was linked to improved skin firmness and hydration, but did not help skin roughness — a proxy for visible wrinkles. 

Benefits appear to accumulate gradually, suggesting that collagen should not be viewed as an “anti-wrinkle ‘quick fix,’ but as a foundational dermal support for individuals seeking holistic skin maintenance,” the researchers said.

Advertisement

“If we define anti-aging as a product or technique designed to prevent the appearance of getting older, then I believe our findings do support this claim for some parameters,” Smith told the BBC. “For example, an improvement in skin tone and moisture is associated with a more youthful-looking appearance.”

Collagen supplementation was linked to reduced pain and stiffness in people with osteoarthritis, with stronger benefits seen over longer periods of use, and showed modest improvements in muscle mass and tendon structure that may support healthy aging. 

Collagen did not significantly improve skin roughness, a marker of visible wrinkles. (iStock)

However, it did not show meaningful results when used as a fast-acting sports performance supplement, and evidence for benefits related to cholesterol, blood sugar, blood pressure and oral health was mixed or inconclusive.

Dr. Daniel Ghiyam, a California-based physician and longevity specialist, said the findings align with what he sees in clinical practice.

Advertisement

CLICK HERE FOR MORE LIFESTYLE STORIES

“Collagen is a targeted support tool, not a foundation of health or performance,” Ghiyam, who was not involved in the study, told Fox News Digital. “When marketed that way, it makes sense. When marketed as a cure-all, it doesn’t hold up to the data.”

The authors noted that while many previous collagen studies have received financial support from the supplement industry, the current review did not receive industry funding.

Experts say collagen supplements may offer modest benefits for skin hydration and joint comfort, but they are not a cure-all. (iStock)

The team called for more high-quality clinical trials examining long-term outcomes, optimal dosages and differences between collagen sources, such as marine, bovine and plant-based alternatives. 

Advertisement

Among its limitations, the review could not determine whether certain forms of collagen work better than others or what the optimal regimen should be. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

While the review included randomized controlled trials, the quality of the studies varied, with newer research generally showing stronger results.

Experts say more data and studies are needed to build on the findings. They also noted that diet plays a crucial role in skin health.

Collagen supplements, often sold as powders or pills, may improve skin elasticity and ease joint pain, experts say. (iStock)

Advertisement

Dr. Erum Ilyas, a Pennsylvania-based dermatologist and chair of dermatology at Drexel University College of Medicine, noted that the review analyzed previously published meta-analyses rather than generating new primary data.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“At this time, I have not seen sufficiently strong independent evidence to routinely recommend collagen supplements to my patients,” Ilyas, who was not involved in the review, told Fox News Digital.

“Although some studies show modest improvements in markers such as hydration and elasticity, there remains limited independent, biopsy-confirmed evidence demonstrating sustained increases in dermal collagen content,” she added.

Fox News Digital has reached out to the researchers for comment.

Advertisement

Related Article

Cosmetic fillers can cause deadly complication, experts warn — but new tech exposes it
Continue Reading

Trending